| Literature DB >> 33152007 |
Ki Hong Kim1,2, Jeong Ho Park1,2, Young Sun Ro1,2, Ki Jeong Hong1,2, Kyoung Jun Song1,3, Sang Do Shin1,2.
Abstract
BACKGROUND: Due to an aging population and the increasing proportion of patients with various comorbidities, the number of patients with acute ischemic heart disease (AIHD) who present to the emergency department (ED) with atypical chest pain is increasing. The aim of this study was to develop and validate a prediction model for AIHD in patients with atypical chest pain. METHODS ANDEntities:
Year: 2020 PMID: 33152007 PMCID: PMC7644067 DOI: 10.1371/journal.pone.0241920
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Patient flow chart.
Comparison of participant characteristics in the development and validation cohorts.
| No. (%) or Median (IQR) | |||||
|---|---|---|---|---|---|
| Original cohort | Training cohort | Validation cohort | |||
| Variables | (N = 4,978) | (N = 3,833) | (N = 1,145) | ||
| Baseline characteristics | |||||
| Age, mean (SD), years | 60.5 (16.6) | 60.3 (16.6) | 60.8 (16.5) | 0.355 | |
| Male sex | 2,701 (54.3%) | 2,087 (54.4%) | 614 (53.6%) | 0.648 | |
| Onset to ED visit time, hours | 7.5 (1.6–46.9) | 7.8 (1.6–48.0) | 6.5 (1.6–27.2) | 0.014 | |
| EMS use | 1,258 (25.3%) | 936 (24.4%) | 322 (28.1%) | 0.013 | |
| Vital signs | |||||
| Systolic blood pressure, mmHg | 146 (130.0–171.0) | 145 (129.0–169.0) | 152 (134.0–175.0) | <0.001 | |
| Diastolic blood pressure, mmHg | 83 (74.0–94.0) | 83 (73.0–93.0) | 84 (75.0–94.0) | 0.001 | |
| Heart rate, beats per min | 79 (69.0–91.0) | 79 (69.0–92.0) | 78 (68.0–90.0) | 0.022 | |
| Respiratory rate, breaths per min | 18 (17.0–20.0) | 18 (18.0–20.0) | 18 (16.0–20.0) | <0.001 | |
| Body temperature, °C | 36.4 (36.2–36.6) | 36.4 (36.2–36.6) | 36.4 (36.2–36.5) | 0.977 | |
| Laboratory data | |||||
| White blood cell count, ×103/μl | 7 (5.7–8.8) | 7.1 (5.7–8.9) | 6.8 (5.5–8.5) | <0.001 | |
| Hemoglobin level, g/dl | 13.4 (12.1–14.7) | 13.4 (12.1–14.7) | 13.3 (11.9–14.5) | 0.003 | |
| Platelet count, ×103/μl | 224 (183.0–268.0) | 225 (185.0–269.0) | 220 (181.0–265.0) | 0.019 | |
| Total bilirubin level, mg/dL | 0.6 (0.5–0.9) | 0.6 (0.5–0.9) | 0.6 (0.5–0.8) | 0.02 | |
| Serum aspartate transaminase level, IU/L | 22 (18.0–29.0) | 22 (18.0–29.0) | 22 (18.0–29.0) | 0.966 | |
| Serum alanine aminotransferase level, IU/L | 20 (14.0–29.0) | 20 (14.0–29.0) | 20 (14.0–29.0) | 0.533 | |
| Serum alkaline phosphatase level, IU/L | 64 (52.0–79.0) | 64 (53.0–79.0) | 63 (51.0–78.0) | 0.093 | |
| Total serum protein level, g/dL | 7.1 (6.7–7.5) | 7.2 (6.8–7.5) | 6.8 (6.5–7.2) | <0.001 | |
| Serum albumin level, g/dL | 4.2 (3.9–4.4) | 4.2 (3.9–4.4) | 4 (3.8–4.3) | <0.001 | |
| Blood urea nitrogen level, mg/dl | 15 (12.0–19.0) | 15 (12.0–19.0) | 15 (12.0–19.0) | 0.671 | |
| Serum creatinine level, mg/dL | 0.9 (0.7–1.1) | 0.9 (0.7–1.1) | 0.9 (0.7–1.0) | 0.486 | |
| Serum sodium level, mmol/L | 140 (138.0–142.0) | 140 (138.0–142.0) | 140 (138.0–142.0) | 0.850 | |
| Serum potassium level, mmol/L | 4.2 (3.9–4.5) | 4.2 (3.9–4.5) | 4.1 (3.9–4.5) | <0.001 | |
| Serum chloride level, mmol/L | 104 (102.0–106.0) | 104 (102.0–106.0) | 104 (102.0–106.0) | 0.001 | |
| Carbon dioxide level, Total, mmol/L | 24.2 (3.1) | 24 (3.0) | 25.1 (3.6) | <0.001 | |
| Serum calcium level, mg/dL | 9.1 (8.7–9.5) | 9.2 (8.8–9.5) | 9 (8.6–9.3) | <0.001 | |
| Serum glucose level, mg/dL | 115 (101.0–141.0) | 115 (102.0–142.0) | 113 (101.0–141.0) | 0.103 | |
| Outcome | |||||
| AIHD, no. (%) | 619 (12.4%) | 453 (11.8%) | 166 (14.5%) | 0.018 | |
| In-hospital mortality, no. (%) | 22 (0.4%) | 21 (0.5%) | 1 (0.1%) | 0.071 | |
IQR, interquartile range; ED, emergency department; EMS, emergency medical service; AIHD, acute ischemic heart disease; no., number; SD, standard deviation.
All continuous variables were preprocessed for extreme values by replacing 1st and 99th percentiles.
Comparison of participants’ characteristics according to study outcome.
| No. (%) or Median (IQR) | |||||
|---|---|---|---|---|---|
| Original cohort | Non-AIHD | AIHD | |||
| Variables | (N = 4,978) | (N = 4,359) | (N = 619) | ||
| Baseline characteristics | |||||
| Age, mean (SD), years | 60.5 (16.6) | 59.5 (17.0) | 67.2 (11.5) | <0.001 | |
| Male sex | 2,701 (54.3%) | 2,264 (51.9%) | 437 (70.6%) | <0.001 | |
| Onset to ED visit time, hours | 7.5 (1.6–46.9) | 7.7 (1.7–46.6) | 5.3 (1.4–47.7) | 0.118 | |
| EMS use | 1,258 (25.3%) | 1,063 (24.4%) | 195 (31.5%) | <0.001 | |
| Vital signs | |||||
| Systolic blood pressure, mmHg | 146 (130.0–171.0) | 146 (130.0–170.0) | 151 (131.0–177.5) | 0.009 | |
| Diastolic blood pressure, mmHg | 83 (74.0–94.0) | 83 (74.0–93.0) | 84 (73.0–94.0) | 0.363 | |
| Heart rate, beats per min | 79 (69.0–91.0) | 79 (69.0–92.0) | 76 (66.0–87.0) | <0.001 | |
| Respiratory rate, breaths per min | 18 (17.0–20.0) | 18 (17.0–20.0) | 18 (18.0–20.0) | 0.703 | |
| Body temperature, °C | 36.4 (36.2–36.6) | 36.4 (36.2–36.6) | 36.4 (36.2–36.5) | <0.001 | |
| Laboratory data | |||||
| White blood cell count, ×103/μl | 7 (5.7–8.8) | 6.9 (5.6–8.7) | 7.8 (6.2–9.8) | <0.001 | |
| Hemoglobin level, g/dl | 13.4 (12.1–14.7) | 13.3 (12.1–14.6) | 13.9 (12.3–15.0) | <0.001 | |
| Platelet count, ×103/μl | 224 (183.0–268.0) | 225 (184.0–270.0) | 217 (179.0–259.5) | 0.012 | |
| Total bilirubin level, mg/dL | 0.6 (0.5–0.9) | 0.6 (0.5–0.9) | 0.6 (0.5–0.8) | 0.911 | |
| Serum aspartate transaminase level, IU/L | 22 (18.0–29.0) | 22 (18.0–28.0) | 25 (19.0–34.0) | <0.001 | |
| Serum alanine aminotransferase level, IU/L | 20 (14.0–29.0) | 19 (14.0–29.0) | 22 (15.0–32.0) | <0.001 | |
| Serum alkaline phosphatase level, IU/L | 64 (52.0–79.0) | 64 (52.0–78.0) | 66 (54.0–80.0) | 0.121 | |
| Total serum protein level, g/dL | 7.1 (6.7–7.5) | 7.1 (6.7–7.5) | 7 (6.7–7.4) | 0.003 | |
| Serum albumin level, g/dL | 4.2 (3.9–4.4) | 4.2 (3.9–4.4) | 4.1 (3.9–4.3) | <0.001 | |
| Blood urea nitrogen level, mg/dl | 15 (12.0–19.0) | 15 (12.0–19.0) | 16 (13.0–20.0) | <0.001 | |
| Serum creatinine level, mg/dL | 0.9 (0.7–1.1) | 0.9 (0.7–1.0) | 1 (0.8–1.1) | <0.001 | |
| Serum sodium level, mmol/L | 140 (138.0–142.0) | 140 (138.0–142.0) | 140 (138.0–141.0) | 0.355 | |
| Serum potassium level, mmol/L | 4.2 (3.9–4.5) | 4.2 (3.9–4.5) | 4.2 (3.9–4.5) | 0.022 | |
| Serum chloride level, mmol/L | 104 (102.0–106.0) | 104 (102.0–106.0) | 104 (102.0–106.0) | 0.219 | |
| Total carbon dioxide level, mmol/L | 24.2 (3.1) | 24.2 (3.1) | 23.9 (3.1) | 0.08 | |
| Serum calcium level, mg/dL | 9.1 (8.7–9.5) | 9.1 (8.7–9.5) | 9.1 (8.7–9.4) | 0.12 | |
| Serum glucose level, mg/dL | 115 (101.0–141.0) | 113 (101.0–139.0) | 129 (109.0–171.0) | <0.001 | |
| Outcome | |||||
| In-hospital mortality, no. (%) | 22 (0.4%) | 13 (0.3%) | 9 (1.5%) | 0.001 | |
IQR, interquartile range; AIHD, acute ischemic heart disease; ED, emergency department; EMS, emergency medical service; no., number; SD, standard deviation.
All continuous variables were preprocessed for extreme values by replacing 1st and 99th percentiles.
Comparison of participants’ cardiac workup results according to the study outcome.
| No. (%) or Median (IQR) | ||||
|---|---|---|---|---|
| Original cohort | Non-AIHD | AIHD | ||
| Variables | (N = 4,978) | (N = 4,359) | (N = 619) | |
| 12-lead ECG conducted in the ED | 4,926 (99.0%) | 4,309 (98.9%) | 617 (99.7%) | 0.094 |
| Troponin I administered in the ED | 4,833 (97.1%) | 4,223 (96.9%) | 610 (98.5%) | 0.029 |
| Troponin I, ng/ml | 0.01 (0.01–0.01) | 0.01 (0.01–0.01) | 0.03 (0.01–0.22) | <0.001 |
| Troponin I ≥0.03, ng/ml | 832 (17.2%) | 520 (12.3%) | 312 (51.1%) | <0.001 |
| CCTA conducted | 1,002 (20.1%) | 928 (21.3%) | 74 (12.0%) | <0.001 |
| CAG conducted | 636 (12.8%) | 17 (0.4%) | 619 (100.0%) | <0.001 |
| PCI conducted | 367 (7.4%) | 1 (<0.1%) | 366 (59.1%) | <0.001 |
IQR, interquartile range; AIHD, acute ischemic heart disease; ED, emergency department; CCTA, coronary computed tomography angiography; CAG, coronary angiography; PCI, percutaneous coronary intervention; ECG, electrocardiography.
Discrimination and test characteristics of acute ischemic heart disease prediction models in the validation cohort.
| Model tested | AUROC(95% CI) | Cutoff probability | TP | FN | TN | FP | Accuracy | Sensitivity | Specificity | PPV | NPV | F1Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Troponin model | 0.73 (0.69–0.77) | 0.112 | 85 | 81 | 894 | 85 | 0.86 | 0.51 | 0.91 | 0.50 | 0.92 | 0.51 |
| LR model | 0.73 (0.70–0.77) | 0.119 | 111 | 55 | 646 | 333 | 0.66 | 0.67 | 0.66 | 0.25 | 0.92 | 0.36 |
| XGB model | 0.75 (0.71–0.79) | 0.127 | 107 | 59 | 659 | 320 | 0.67 | 0.64 | 0.67 | 0.25 | 0.92 | 0.36 |
*Cutoff was calculated using the Youden index.
†p-value for comparison of AUROC with baseline models: 0.600 for the troponin model and 0.277 for the logistic regression model.
AUROC, area under the receiver operating characteristic curve; 95% CI, 95% confidence interval; TP, true positive; FN, false negative; TN, true negative; FP, false positive; PPV, positive predictive value; NPV, negative predictive value; LR, logistic regression; XGB, extreme gradient boosting.
Fig 2Calibration plots for acute ischemic heart disease in the validation cohort.
The observed probability of acute ischemic heart disease (with a 95% confidence interval) is plotted against predicted good neurological recovery by 10% intervals of the predicted probability. Point size indicates the relative number of observations in a group. AIHD, acute ischemic heart disease.
Fig 3A. Partial dependence plot for the A) logistic regression model and B) extreme gradient boosting model. The orders of each plot are according to the variable importance of each model. GOT, aspartate transaminase; WBC, white blood cell count; GPT, alanine aminotransferase; ALP, alkaline phosphatase; BUN, blood urea nitrogen; DBP, diastolic blood pressure; CO2, carbon dioxide; SBP, systolic blood pressure; EMS, emergency medical service.